Latest Breaking News On - Bykate burba - Page 1 : comparemela.com

Bulevirtide monotherapy may prevent decompensation but not HCC in HDV, cirrhosis

Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients. “Bulevirtide, the first-in-class entry inhibitor, has been approved by EMA for treatment of compensated chronic hepatitis delta,” Elisabetta Degasperi, MD,

Kristen dowdBykate burbaGranda ospedale maggiore policlinico

Substantial proportion of PSC patients listed for LT due to dysplasia have no neoplasia

Researchers identified bile duct dysplasia or cancer in most explanted livers with an indication of biliary dysplasia, although as many as 41% had no signs of neoplasia, according to a study of patients with primary sclerosing cholangitis. “Primary sclerosing cholangitis, in short PSC, is one of the leading causes of liver transplantation in the Nordic countries with a high risk of

Sigurd brederHeather bieleBykate burbaResearch centerNordic liver transplant registry

Mebeverine not superior to placebo in pediatric IBS; active drug labeling improved efficacy

Mebeverine not superior to placebo in pediatric IBS; active drug labeling improved efficacy
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandHeather bieleBykate burbaMarca benningaDigestive disease week

Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

United statesBykate burbaEvans dellonHeather bieleUniversity of north carolina school medicineEsophageal diseasesNorth carolina schoolDigestive diseaseDigestive disease weekEoe histology scoring systemEoe endoscopic reference scorePatient global impressionDysphagia symptom questionnaire

Blood-based screening test detects CRC with nearly 80% sensitivity in average-risk adults

WASHINGTON — A blood-based screening test detected colorectal cancer with a sensitivity of 79.2% and a specificity of 91.5% among average-risk adults aged 45 to 85 years, according to research presented at Digestive Disease Week. “Adherence to colon cancer screening tests is suboptimal with current options of stool-based tests and colonoscopy,” Aasma Shaukat, MD, MPH, director

District of columbiaUnited statesAasma shaukatHeather bieleMaryh glickmanBykate burbaGrossman school of medicineDigestive diseaseDigestive disease week